Norovirus Market Size in the 7MM is Estimated to Exceed USD 545.02 Million by 2035

The norovirus market size reached a value of USD 140.07 million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 545.02 million by ​2035​, exhibiting a growth rate (CAGR) of 31.1% during ​2025-2035​.

Norovirus is a virus that can spread very easily, resulting in inflammation of the stomach and intestines, diverting normal bodily functions such as vomiting and diarrhea to abnormal ones, alongside stomach cramps and fever. Places like hospitals, schools, cruise ships, and nursing homes that tend to get crowded become breeding grounds for its transmission, marking it as a virus that poses a risk to global public health systems.

People infected with norovirus usually recover without medical assistance. In extreme cases, however, complications arise, particularly among the elderly, young children, and those with weakened immune systems. This susceptibility is what has fueled the need for diagnostic measures, vaccines, and other supportive care, marking the rise of the Norovirus industry in the world.

Request for a sample of this report: https://www.imarcgroup.com/norovirus-market/requestsample

In 2025, one of the most noticeable advancements is likely to be in diagnostic technologies. Among the recently adopted techniques, rapid molecular testing and point-of-care diagnostics are known to expand the identification metrics for norovirus infections. This requirement of accurate diagnosis is even more vital in healthcare environments, where the healthcare personnel's ability to act immediately avoids larger outbreaks. The introduction of advanced polymerase chain reaction (PCR) testing and immunoassay testing systems have improved the accuracy of these tests, contributing to enhanced patient management and infection control.

Vaccines are still in clinical trials but are alongside other candidates competing to be the first commercially available vaccine on the market. Despite lacking pertinent vaccines beforehand, the advancement of mRNA frameworks has begun catalyzing innovations for Norovirus vaccines at the same time as preventative healthcare been placed under the spotlight due to the success of mRNA frameworks. After their approval, these vaccines are bound to increase the market growth in areas infected populations regardless of region.

From the developed to developing countries, the frequency of Norovirus infections are soaring which is a primary cause of the expansion in market growth. The means for transportation, tourism, and globalization have all drastically increased the risk of Norovirus spreading. This has also aided both local and international health organizations to funnel resources towards monitoring, education, research, and surveillance which in turn benefits the scope of the market.

The Norovirus market is set to expand in 2025 due to improving awareness of sanitary practices alongside government policies aimed towards infections diseases. Even with these efforts in place, the virus's remarkable ability to withstand death and stay alive for exceptionally long periods of time on surfaces ensures outbreaks happen frequently. This stubborn nature of the virus illuminates the need for ongoing efforts in prevention research.

Ask the Analyst for Customization and Get Full Insights with TOC: https://www.imarcgroup.com/request?type=report&id=35578&flag=E

This report also provides a detailed analysis of the current norovirus marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Competitive Landscape With Key Players:

The competitive landscape of the norovirus market has been studied in the report with the detailed profiles of the key players operating in the market.

HilleVax
Vaxart
Moderna Therapeutics

IMARC Group Offers Other Reports:

Age-Related Macular Degeneration Market https://www.imarcgroup.com/age-related-macular-degeneration-market

Autism Spectrum Disorder Markethttps://www.imarcgroup.com/autism-spectrum-disorder-market

Aplastic Anemia Market: https://www.imarcgroup.com/aplastic-anemia-market

Duchenne Muscular Dystrophy Market:https://www.imarcgroup.com/duchenne-muscular-dystrophy-market

Contact US:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.

IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

This release was published on openPR.